Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Dimopoulos, M, Weisel, K, Moreau, P, Anderson, LD, White, D, San-Miguel, J, Sonneveld, P, Engelhardt, M, Jenner, M, Corso, A, Dürig, J, Pavic, M, Salomo, M, Casal, E, Srinivasan, S, Yu, X, Nguyen, TV, Biyukov, T, Peluso, T & Richardson, P 2021, 'Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse', Leukemia, vol. 35, no. 6, pp. 1722-1731. https://doi.org/10.1038/s41375-020-01021-3

APA

Dimopoulos, M., Weisel, K., Moreau, P., Anderson, L. D., White, D., San-Miguel, J., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Casal, E., Srinivasan, S., Yu, X., Nguyen, T. V., Biyukov, T., Peluso, T., & Richardson, P. (2021). Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia, 35(6), 1722-1731. https://doi.org/10.1038/s41375-020-01021-3

CBE

Dimopoulos M, Weisel K, Moreau P, Anderson LD, White D, San-Miguel J, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Casal E, Srinivasan S, Yu X, Nguyen TV, Biyukov T, Peluso T, Richardson P. 2021. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia. 35(6):1722-1731. https://doi.org/10.1038/s41375-020-01021-3

MLA

Vancouver

Author

Dimopoulos, Meletios ; Weisel, Katja ; Moreau, Philippe ; Anderson, Larry D ; White, Darrell ; San-Miguel, Jesus ; Sonneveld, Pieter ; Engelhardt, Monika ; Jenner, Matthew ; Corso, Alessandro ; Dürig, Jan ; Pavic, Michel ; Salomo, Morten ; Casal, Eva ; Srinivasan, Shankar ; Yu, Xin ; Nguyen, Tuong Vi ; Biyukov, Tsvetan ; Peluso, Teresa ; Richardson, Paul. / Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM) : outcomes by prior treatment at first relapse. In: Leukemia. 2021 ; Vol. 35, No. 6. pp. 1722-1731.

Bibtex

@article{b8cfabdf25f34147a43509583b897530,
title = "Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse",
abstract = "In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%; P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments.",
author = "Meletios Dimopoulos and Katja Weisel and Philippe Moreau and Anderson, {Larry D} and Darrell White and Jesus San-Miguel and Pieter Sonneveld and Monika Engelhardt and Matthew Jenner and Alessandro Corso and Jan D{\"u}rig and Michel Pavic and Morten Salomo and Eva Casal and Shankar Srinivasan and Xin Yu and Nguyen, {Tuong Vi} and Tsvetan Biyukov and Teresa Peluso and Paul Richardson",
year = "2021",
month = jun,
doi = "10.1038/s41375-020-01021-3",
language = "English",
volume = "35",
pages = "1722--1731",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

RIS

TY - JOUR

T1 - Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM)

T2 - outcomes by prior treatment at first relapse

AU - Dimopoulos, Meletios

AU - Weisel, Katja

AU - Moreau, Philippe

AU - Anderson, Larry D

AU - White, Darrell

AU - San-Miguel, Jesus

AU - Sonneveld, Pieter

AU - Engelhardt, Monika

AU - Jenner, Matthew

AU - Corso, Alessandro

AU - Dürig, Jan

AU - Pavic, Michel

AU - Salomo, Morten

AU - Casal, Eva

AU - Srinivasan, Shankar

AU - Yu, Xin

AU - Nguyen, Tuong Vi

AU - Biyukov, Tsvetan

AU - Peluso, Teresa

AU - Richardson, Paul

PY - 2021/6

Y1 - 2021/6

N2 - In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%; P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments.

AB - In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%; P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments.

UR - http://www.scopus.com/inward/record.url?scp=85090306164&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-01021-3

DO - 10.1038/s41375-020-01021-3

M3 - Journal article

C2 - 32895455

VL - 35

SP - 1722

EP - 1731

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -

ID: 62110222